Metastasis dormancy in estrogen receptor-positive breast cancer.
about
Dynamic interplay between adhesion surfaces in carcinomas: Cell-cell and cell-matrix crosstalkTargeting Breast Cancer MetastasisCausal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving SurgeryTumor cell dormancyBreast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures.Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.In vivo models in breast cancer research: progress, challenges and future directions.miR-639 promotes the proliferation and invasion of breast cancer cell in vitro.FOSL2 positively regulates TGF-β1 signalling in non-small cell lung cancer.Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cellsMarkers for the identification of late breast cancer recurrence.The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brainEstrogen Enhances the Cell Viability and Motility of Breast Cancer Cells through the ERα-ΔNp63-Integrin β4 Signaling Pathway.Modeling selective elimination of quiescent cancer cells from bone marrow.Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer PatientsLate recurrence of breast carcinoma metastasis to the hypopharynx: a case reportAnnual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche.Novel ERα positive breast cancer model with estrogen independent growth in the bone microenvironment.Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome.Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells.New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.ΔNp63α induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvementLiver metastatic disease: new concepts and biomarker panels to improve individual outcomes.Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis.Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance.Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases.Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2- subtype breast cancer.Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastasesA Facile, In Vitro 384-Well Plate System to Model Disseminated Tumor Cells in the Bone Marrow Microenvironment.Extracting microtentacle dynamics of tumor cells in a non-adherent environment.Hallmarks of Bone Metastasis.Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary.Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
P2860
Q26765201-A91E07BF-B6F8-4358-8422-A669622AEA1BQ26783925-AD2E0F42-A09D-4733-81A9-DCD24F418A57Q28069804-BDD4EF62-580F-4A88-BB46-5DA7BB5803F6Q28073065-CA152E83-6E23-4E90-B59D-E63D25B82D13Q30248838-EF597EAB-EFF9-4AC7-9585-C150D41317E9Q31031200-0610804B-1821-4870-94DA-0071A3D15ED8Q33588117-5BE34DE0-3A09-486D-AEEC-0A8003A557D6Q33731757-0CAC709A-0BA9-421A-B8CD-E1CE911DA6DBQ34466194-3A247DB7-4C6D-48EC-A5AC-A5E00D4C72B8Q35000639-FD089CA8-825E-466B-BD44-BFA8E5BFB2F0Q35018949-C2FD6FD3-6DDD-4426-BEFB-9464ED1A5078Q35687321-1287884F-53CB-4C7F-B6F2-D4E87DCBED1DQ35914389-D8918C1E-0BFB-49D9-8A5D-42BF1EFC3474Q36360112-F3DDEBD6-DEEC-4D72-B923-58C0CB7F0222Q36545100-A5700F7A-5D7B-41F2-94AC-7EC9BD1DE6B7Q36653686-BA97842C-71A1-4E3B-B592-98C66D710010Q36894951-32AA8448-8FC6-4DF5-B9BF-FDB32F7347D9Q37065597-570E5132-D7F7-4527-BF6C-94C66C2CD82DQ37340509-CED0FE8E-0A7C-42BE-BF5A-E29F0EB6DE5BQ37580311-C176E7DA-8476-403E-A272-3546FA2CC9EEQ38253835-F0F3FFDD-631C-4CD0-8E13-A4D395D93D96Q38381907-BC1CBB0C-29AA-45CF-92B3-5E562AB55887Q38443838-010D480C-4D49-4606-93A3-BFBD01404050Q38550876-8A28FD31-6D7E-478D-8C4F-754D118B1F92Q38809040-51DBE9BA-9792-412C-A94C-796AF8145719Q38818271-AFB5C727-83B9-42A2-BB13-D9517ACCA4BBQ38842969-80C5D65A-FF39-4049-8A23-CF27B85F110DQ38931957-C230A4EA-BDF1-4449-B12F-0F8B010F8F26Q39214999-7AAD4FAA-A8BE-4705-A6B0-2EC39D352E09Q39451397-3F7080F1-0303-40B7-A110-4855F302782CQ40581595-33420867-3893-4B64-87EF-D34AFF015019Q41725997-8F7991E1-CAB8-46E8-AECB-B27B88B752E2Q41815223-FEEFB2A7-4AB2-4F35-8C62-36EC14C86FA3Q42078197-967C4388-430D-46EF-A155-47B50DE39978Q42080797-A03D5819-966D-46C8-A134-DFFD6F53AC35Q47445458-6886E566-03C9-4E6E-B8A5-42EAF4983820Q47562369-051F5813-DDDA-4B01-A5C5-E58925A9DEEBQ48303279-A2255EEB-7598-4824-BDCC-D57705B44DE2Q48685076-CA85D5FF-7B15-4C3C-8D54-303AC1A47875Q49834126-DDAFCAF0-A36F-4CBA-8AAF-060A838270A5
P2860
Metastasis dormancy in estrogen receptor-positive breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metastasis dormancy in estrogen receptor-positive breast cancer.
@en
Metastasis dormancy in estrogen receptor-positive breast cancer.
@nl
type
label
Metastasis dormancy in estrogen receptor-positive breast cancer.
@en
Metastasis dormancy in estrogen receptor-positive breast cancer.
@nl
prefLabel
Metastasis dormancy in estrogen receptor-positive breast cancer.
@en
Metastasis dormancy in estrogen receptor-positive breast cancer.
@nl
P2093
P2860
P1476
Metastasis dormancy in estrogen receptor-positive breast cancer
@en
P2093
C Kent Osborne
Mario Giuliano
Meghana V Trivedi
Rachel Schiff
P2860
P304
P356
10.1158/1078-0432.CCR-13-0838
P407
P577
2013-12-01T00:00:00Z